Cellnovo launches mobile-connected diabetes management system
29 February 2012
Cellnovo has launched a mobile-connected diabetes management
system, and announced the start of a usability trial to investigate
insulin pump technology for patients with type 1 diabetes.
The trial will also be the first in which all clinical data is
captured remotely, in real-time; using the mobile data connectivity
of the Cellnovo system.
Cellnovo's diabetes management system comprises an insulin pump
that connects wirelessly to an intuitive 'app-based' touch-screen
handset. The handset features an integral blood glucose monitor, an
activity monitor and a mobile (GSM) data connection to a
comprehensive web-based clinical management system.
patients will be able to track and manage their diabetes; securely
sharing all clinical information through the web so that they, their
doctors, nurses and family members can ensure sustained and
effective diabetic control.
Principal Investigator of the Cellnovo usability trial, and
world-leading authority on insulin pump therapy, Professor John
Pickup of King's College London School of Medicine, remarked, "This
clinical trial is not just the world's first with a mobile-connected
insulin infusion system, it is also the first clinical trial in
which the care team and patients can simultaneously observe and
evaluate patient data in real-time, anywhere in the world."
Co-trialist, Dr Mark Evans of Addenbrookes Hospital in Cambridge,
commented, "This technology represents a entirely new model for the
management of diabetes and one that could be of direct and long-term
financial benefit to the NHS. The effective management of diabetes
requires masses of information.
The more information we have, and the more rapidly we have it,
the better job we can do of using our resources efficiently to
prevent the devastating long-term complications of diabetes. The
Cellnovo system is the world's first both to automate and deliver
instantly the information we need a task achieved through the
thoughtful and thorough integration of consumer technology, such as
wireless and cellular, with medical sensor and precision pump
Co-trialist, Professor Stephen Greene of the University of Dundee
added, "The Cellnovo system provides us immediate access to the
clinical status of all our patients on a single screen. With
accurate and current information we can identify and address
problems immediately that, otherwise, might go unnoticed for months,
contributing to excess cost and potentially tragic patient
"In this clinical trial we will be the first to explore these new
opportunities in diabetes patient management and hope to uncover new
ways to improve and extend care, optimise workflow and drive cost
William F McKeon, Cellnovo Chief Executive Officer added, "The
launch of the Cellnovo system marks a new era in medicine where
mobile connectivity is routinely embedded in medical devices. We
draw upon the convenience of mobile technology in so many aspects of
our lives: email, photos, social networking and banking.
"It is now time that our most precious asset, our health,
benefits from the real-time information flow that is made possible
with an in-built mobile connection. We are moving into an era where
our doctors will routinely detect health issues over the web, before
they worsen; and where patients and family members have the peace of
mind that dangerous and costly emergencies can be avoided as early
signs are immediately spotted."
"The Cellnovo usability trial will be conducted in ten of the
leading diabetes centres across the UK and will involve 100
patients, both adults and children. Such scale is unprecedented for
a trial of insulin infusion technology and its usability," said Dr
Reman McDonagh, Director of Clinical and Physician Relations for
Type 1 diabetes is routinely managed with pump technology
throughout much of Europe and North America where 20-25% of patients
gain benefit from therapy that mimics the body's normal production
of insulin. Yet the UK lags behind, with 96% of patients having to
rely on multiple daily injections.
By introducing a unique system that uses cellular data and touch
screen technology, Cellnovo aims to eliminate the barriers to
adoption of insulin pump therapy; simplifying and reducing the
workload for doctors and nurses, while also improving the quality of
insight and diabetes management achieved by patients.
Type 1 diabetes affects 250,000 UK patients for whom the prospect
of poor diabetic control can lead to blindness, nerve damage and
death. Caring for diabetes accounts for 10% of the NHS budget, a
significant proportion of which is focused on type 1, a growing
challenge that affects 4% more UK patients each year. Type 1
diabetes can only be managed by the daily or constant administration
of insulin, replacing the role of the pancreas that for these
patients has become incapable of producing insulin, which is vital
for the metabolism of carbohydrates.